Mustang Bio Inc (NASDAQ:MBIO)

2.72
BATS BZX Real-Time Price
As of 3:19pm ET
 0.00 / 0.00%
Today’s Change
2.42
Today|||52-Week Range
5.22
-28.27%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$248.6M

Company Description

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Contact Information

Mustang Bio, Inc.
377 Plantation Street
Worcester Massachusetts 01605-2245
P:(781) 652-4500
Investor Relations:

Employees

Shareholders

Mutual fund holders14.47%
Other institutional14.17%
Individual stakeholders12.97%

Top Executives

Manuel LitchmanPresident, Chief Executive Officer & Director
Brian AchenbachSenior Vice President-Finance & Controller
Knut NissChief Technology Officer
Robyn M. HunterSecretary & Treasurer
Jaclyn JaffeHead-Investor Relations